These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7488428)

  • 1. The effect of different dose levels of degradable starch microspheres (Spherex) on the distribution of a cytotoxic drug after regional administration to tumour-bearing rats.
    Teder H; Johansson CJ; d'Argy R; Lundin N; Gunnarsson PO
    Eur J Cancer; 1995 Sep; 31A(10):1701-5. PubMed ID: 7488428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.
    Double JA; Bibby MC; Loadman PM; Bloomer JC
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1355-60. PubMed ID: 3181256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved antitumor effect of the nitrosourea drugs tauromustine (TCNU) and carmustine (BCNU) on a rat liver adenocarcinoma after hepatic arterial administration with degradable starch microspheres.
    Roos G; el Hag IA; Teder H; Stenram U
    Anticancer Res; 1991; 11(1):13-6. PubMed ID: 2018346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
    Bibby MC; Loadman PM; al-Ghabban AF; Double JA
    Br J Cancer; 1992 Mar; 65(3):347-50. PubMed ID: 1558786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of different dosages of degradable starch microspheres (Spherex) on the distribution of doxorubicin regionally administered to the rat.
    Teder H; Johansson CJ
    Anticancer Res; 1993; 13(6A):2161-4. PubMed ID: 8297129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069.
    Roos G; Christensson PI; el Hag IA; Jakobsson B; Teder H; Stenram U
    Anticancer Res; 1993; 13(3):635-41. PubMed ID: 8317891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor effect of a novel nitrosourea, tauromustine, at intravenous administration in rat. Cure of hepatomas.
    Roos G; el Hag IA; Christensson PI; Stenram U
    Anticancer Res; 1991; 11(5):1763-6. PubMed ID: 1837442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).
    Hartley-Asp B; Christensson PI; Gunnarsson K; Gunnarsson PO; Jensen G; Polacek J; Stamvik A
    Invest New Drugs; 1988 Apr; 6(1):19-30. PubMed ID: 3410663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.
    Bibby MC; Double JA; Morris CM
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1361-4. PubMed ID: 3181257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex).
    Johansson CJ
    Clin Pharmacokinet; 1996 Sep; 31(3):231-40. PubMed ID: 8877252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice.
    Hill SR; Bibby MC
    Cancer Chemother Pharmacol; 1994; 34(1):57-62. PubMed ID: 8174203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spherex (degradable starch microspheres) chemo-occlusion--enhancement of tumor drug concentration and therapeutic efficacy: an overview.
    Håkansson L; Håkansson A; Morales O; Thorelius L; Warfving T
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-100-S6-109. PubMed ID: 9151924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
    Gunnarsson PO; Vibe-Petersen J; Macpherson JS; Warrington PS; Polacek J; Ellman M; Hansen HH; Smyth JF
    Cancer Chemother Pharmacol; 1989; 23(3):176-80. PubMed ID: 2924375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.
    Whittle IR; MacPherson JS; Miller JD; Smyth JF
    J Neurosurg; 1990 May; 72(5):721-5. PubMed ID: 2157825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental cerebral and plasma pharmacokinetic studies of TCNU: implications for brain tumour chemotherapy.
    Whittle IR; Macpherson JS; Smyth J; Miller JD
    Br J Neurosurg; 1987; 1(3):365-8. PubMed ID: 3268132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporary blood flow stasis with degradable starch microspheres (DSM) for liver metastases in a rat model.
    Flowerdew AD; Richards HK; Taylor I
    Gut; 1987 Oct; 28(10):1201-7. PubMed ID: 3678948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres.
    Teder H; Erichsen C; Christensson PI; Jönsson PE; Stenram U
    Cancer Drug Deliv; 1987; 4(3):169-76. PubMed ID: 2453264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose.
    Hartley-Asp B; Hansson K; Vibe-Petersen J; Hansen HH; Polacek J; Ellman M; Gunnarsson PO
    Cancer Chemother Pharmacol; 1996; 38(4):309-16. PubMed ID: 8674152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma.
    Hill SR; Pollard LA; Bibby MC
    Anticancer Res; 1992; 12(6B):2169-75. PubMed ID: 1295464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of degradable starch microspheres on liver uptake of 5-fluorouracil after hepatic artery injection in the rat.
    Teder H; Aronsen KF; Björkman S; Lindell B; Ljungberg J
    J Pharm Pharmacol; 1986 Dec; 38(12):939-41. PubMed ID: 2880975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.